INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Antimicrobial Resistance: Impacts, Challenges, and Future Prospects

Akshat Markam*, Swati Khare, Dr. Jitendra Banweer

Sage University, Bhopal.

ARTICLE INFO

Published: 28 May 2025

Keywords:
Antimicrobial resistance, multidrug-resistant organisms, One Health, surveillance, artificial intelligence, public health, antimicrobial stewardship

DOI:
10.5281/zenodo.15535325

ABSTRACT

Antimicrobial resistance (AMR) is a global health concern driven by the misuse and overuse of antibiotics in various industries, leading to the emergence of resistant microorganisms. The history of AMR dates back to the discovery of penicillin, with the emergence of multidrug-resistant pathogens posing serious challenges to healthcare systems worldwide. Antibiotic abuse in human and veterinary medicine, agriculture, and animal husbandry contributes to the spread of resistance genes, causing a "Silent Pandemic" that can be larger than other mortality causes by 2050. Humans and animals are both affected by AMR, with resistant microorganisms causing problems in the management of infections. There are many mechanisms, such as enzymatic modification and biofilm formation, through which microbes can withstand the effects of antibiotics. The lack of effective antibiotics threatens routine medical procedures and could lead to millions of deaths annually if left unchecked. The economic burden of AMR is significant, with projected losses in the trillions of dollars and significant financial loads on healthcare systems and agriculture. Artificial intelligence has been explored as one of the means of addressing AMR through improving diagnostics and treatment strategies, though with the limitations of data quality and algorithmic prejudice. For effective management of AMR, the implementation of One Health strategy by considering human, animal, and environment is critical. This involves improving surveillance networks, promoting stewardship programs, and investing in R&D for the production of new antimicrobial agents. Global cooperation, public awareness, and education are the keys to combating AMR and preserving the effectiveness of antibiotics for generations to come.

INTRODUCTION

Antimicrobial resistance (AMR) is the most severe global public health threat in the 21st century. AMR is when microbes, such as bacteria, fungi, parasites, and viruses, through evolutionary adaptation, become resistant to antimicrobial drugs, such as antibiotics, which are usually

***Corresponding Author:** Akshat Markam
Address: *IIMT College of Pharmacy, Greater Noida, Uttar Pradesh-201306.*
Email ✉: Sage University, Bhopal
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

applied for curing infection. The widespread issue of AMR is primarily caused by the effects of the abuse or misuse of antibiotics in different situations, prominent among them being clinical treatment, agriculture, animal health, war crisis and food systems. Often termed as the "Silent Pandemic", AMR has timely and effective measures to be implemented rather than keeping oneself waiting for a future scenario. Lacking preventive action, by the year 2050 AMR could easily surpass all other causes of mortality worldwide. Worldwide, estimates indicate that 1.2 million direct deaths due to AMR were reported in 2019, projected to rise to around 10 million deaths by 2050 if adequate measures are not instituted to halt AMR. The aim of this study is to extensively review antimicrobial resistance (AMR), summarizing its past history, describing the mechanism behind it, and ascertaining its massive impact on human and animal populations. It further aims to analyze past and current prevalence rates, project future burdens, explore the role of artificial intelligence in combating AMR, respond to associated challenges, and provide actionable recommendations towards effective mitigation strategies and future research.

2. Historical Background and Development of AMR

The history of AMR development dates back to Alexander Fleming's discovery of penicillin in 1928. Ironically enough, resistance set in soon afterward. Penicillin-resistant Staphylococcus aureus was reported as early as 1942, and resistance continued to evolve when new antibiotics entered the market. The 1960s saw the emergence of methicillin-resistant S. aureus (MRSA), while the 1980s were marked by an epidemic outbreak of MDR tuberculosis globally. The 1990s were marked by increased resistance in gram-negative bacteria such as E. coli and K. pneumoniae, particularly due to the spread of extended-spectrum β-lactamases (ESBLs). These points emphasize the adaptive flexibility of microbes under selective pressure. Widespread use of antibiotics in agriculture to prevent disease and promote growth has been instrumental in disseminating resistance. Phasing out by drug companies of antibiotic research due to unprofitability continues to exacerbate the crisis.

3. Mechanisms of Resistance and microbes involved

Antimicrobial resistance (AMR) is caused by a number of factors, including natural selection, inappropriate and excessive use of antibiotics, inadequate access to clean water and sanitation, and consumption of substandard or counterfeit drugs. Antibiotic misuse involves partial treatment, inappropriate prescription, and self-medication. Bacteria surviving incomplete courses of antibiotics may result in resistance. Antibiotic prescription of viral illnesses, usage of expired medications, or self-medication without supervision also contributes to AMR. Poor sanitation and hygiene allow the spread of infectious diseases, which in turn causes excessive usage of antibiotics and hence resistance. Low-quality medicines with incorrect dosages or low active ingredient levels also lead to ineffective treatment and stimulate the growth of resistance. Microbes have evolved many ways to recover from exposure to antibiotics. This allows them to become resistant to antimicrobial substances that once used to kill them. Bacteria and other infections adapt by restructuring themselves and implementing metabolic pathways so they can destroy or evade drugs. Key mechanisms of resistance include enzymatic degradation or alteration of substrate antibiotics, reduced drug penetration into cells, alteration of target sites such as ribosomes, alterations in metabolic processes, and the increased activity of efflux pumps that expel antibiotics before they are able to achieve effective levels. Bacteria also form biofilms—dense, surface-associated populations that restrict antibiotic penetration and offer further protection. Bacteria are also capable of acquiring resistance genes from other organisms, even from different species, through horizontal gene transfer by plasmids and other mobile genetic elements. These gene units are likely to carry multiple resistance determinants, making multidrug resistance (MDR) widely disseminated within bacterial populations quickly. This genetic flexibility allows microorganisms to adapt quickly to new antimicrobial therapy. In the past decades, different pathogens have developed AMR through different mechanisms. Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to numerous antibiotics because of mecA and mecC gene mutations and horizontal gene transfer. Carbapenem-resistant Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli have evolved carbapenemase genes, usually plasmid-mediated. Extended-spectrum beta-lactamase (ESBL)-producing E. coli are penicillin- and cephalosporin-resistant because of plasmid-acquired ESBL genes. Mycobacterium tuberculosis (MDR-TB) with multidrug resistance carries mutations that make anti-TB drugs ineffective. Acinetobacter baumannii and Neisseria gonorrhoeae have both developed resistance through gene acquisition and mutations. Fluconazole-resistant Candida species target high-risk populations, while viruses like HIV and influenza viruses tend to develop resistance mutations. Emergence of MDR pathogens worldwide requires urgent adoption of concerted measures against AMR.

4. Human and Animal Health Impacts

Antimicrobial resistance (AMR) is a growing global health danger to humans and animals. It results from excessive and inappropriate use of antibiotics in healthcare, agriculture, and veterinary practice, accelerating the emergence of drug-resistant microorganisms, known as "superbugs." The resistant microbes render treatment more complicated, leading to prolonged illnesses, higher medical costs, and higher death rates. The slow process of new antibiotic discovery also contributes to the problem, with the rise in resistance outpacing innovation. AMR has become a 21st-century public health crisis that renders previously curable infections difficult to treat. When first-line drugs fail, more toxic and expensive second- and third-line drugs are then required. This leads to longer hospital stays, additional economic burden for individuals and health systems, and higher complication or fatality rates. Common practices like surgeries, chemotherapy, and organ transplants become immensely riskier without effective antimicrobials. Most cause for concern among the "ESKAPE" pathogens—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species—are responsible for severe issues within hospitals. AMR also poses a threat to food security and agriculture. Excessive use of antibiotics in veterinary medicine for controlling disease and growth promotion has created reservoirs of resistant bacteria such as Salmonella and Campylobacter. These pathogens are transmitted to humans through food, direct contact, or environmental route. Resistant microbes are also transmitted through manure fertilizers and contaminated water, infecting plants and ecosystems. Resistance genes are also carried by wildlife and environmental microorganisms, creating a cycle of transmission through feedback. The economic consequences are severe, with projected losses of $3–4 billion in livestock alone within the coming decades. AMR undermines food security, trade, and country health systems. To combat AMR, an integrated One Health approach—aligning human, animal, and environmental health interventions—is required to curtail transmission effectively and safeguard global health.

5. Global Prevalence and Surveillance

Data from Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control (ECDC), and World Health Organization's Global Antimicrobial Resistance Surveillance System (GLASS) supports the occurrence of AMR worldwide. The United States alone accounts for more than 2.8 million cases of AMR and more than 35,000 deaths annually. Europe loses more than 33,000 AMR-related deaths annually, with an estimated economic burden of more than €1.5 billion. Poor healthcare infrastructure and surveillance conditions in low- and middle-income countries (LMICs) exacerbate the AMR issue. In India alone, there are over 50,000 newborn deaths due to sepsis by resistant bacteria. Resistance rates against ciprofloxacin among E. coli vary from 8.4% to 92.9%. These disparities are a result of differential use of antibiotics, regulatory environments, and access to health care.

6. Future Projections and Economic Burden

The prospects for the future are bleak, as shown by a study ordered by the government in the United Kingdom. The study estimated that by 2050, there could be about 10 million deaths each year due to diseases that are antibiotic-resistant. Minor injuries and uncomplicated infections could again prove fatal, and major surgeries such as organ transplants, chemotherapy, or hip replacement could become perilously dangerous. The economic cost of AMR will total $100 trillion USD in 2050. Low- and middle-income nations will bear the greatest greatest burden as the expansion of bacterial resistance outmatches new antimicrobial developments. In the meantime, limitations in resources impede the accessibility of currently available high-cost therapies. Global coordination is woefully absent, with piecemeal containment strategies failing to keep pace with the evolutionary potential of pathogenic bacteria subjected to ongoing exposure to humanity's pervasive antimicrobial deployment in healthcare, agriculture, and the environment. Adding to direct mortality and economic effects, the growing ineffectiveness of antimicrobials would severely disable contemporary medicine while allowing the return of bacterial infections that had become historically uncommon due to antibiotic treatments. Cancer patients, the immunocompromised, and patients undergoing surgical procedures make up groups particularly exposed to newly developing extensively- or pan-drug-resistant bacterial strains. Furthermore, the combined weight of prevalent infectious ailments such as pneumonia, tuberculosis, and gastrointestinal disorders could balloon extensively in a post-antibiotic world. Finally, the accelerated exhaustion of effective antimicrobials compromises decades of medicosocial development while foreshadowing reverting to man's earlier life, when bacterially caused infection represented predominant environ-medical evils.

7. The Role of Artificial Intelligence in Combatting AMR

Today, artificial intelligence finds application across a number of areas in healthcare, proving its widespread use in contemporary medical practices. A number of studies that have been published on artificial intelligence prove its efficiency in fighting antimicrobial resistance by identifying rapidly the patterns of bacterial behavior and adapting treatment accordingly. These technologies hold massive potential for more efficient and tailored strategy in fighting the global health risk posed by antimicrobial-resistant pathogens. The advent of artificial intelligence (AI) and machine learning methods offers promising potential to enhance antimicrobial stewardship and precision medicine strategies for countering the urgent threat of AMR. As AMR erode the effectiveness of conventional antibiotic regimens against increasingly widespread "superbugs", AI tools that can augment diagnostics, refine prescribing patterns, and resupply dwindling drug pipelines will prove invaluable. In healthcare delivery, AI incorporation represents an evolutionary progression from conventional antibiotic stewardship programs based on specialized personnel monitoring and formulary restriction policies. Complex neural networks and predictive algorithms can detect positive cultures or probable infections earlier through clinical presentations to enable quicker targeted therapy. Likewise, AI prescription advisors can incorporate hospital metadata regarding local microbiology, patient-specific factors, and treatment guidelines to suggest best antibiotic choice. These AI antibiotic consultants restrict empirical broad agent overuse. Just as human clinicians tend to overprescribe antibiotics in the lack of absolute diagnostics, smart safeguards that weigh infection risk against resistance formation can be priceless. AI implementation can also increase stewardship programs' ability to monitor patients continuously on proper antibiotic discontinuation post-cultures. Beyond direct care, AI-driven epidemiology surveillance identifying local resistance outbreaks can more effectively inform dynamic formulary policies. Computational methods mining -omics databases, published research, and molecular libraries could also uncover new drug targets or chemical scaffolds for antibiotic discovery pipelines increasingly vacated by pharmaceutical firms. Together, AI stewardship complementing established antimicrobial regulation and precision medicine initiatives represent a seminal evolutionary step toward maintaining antibiotic effectiveness. Some limits remain on what artificial intelligence, modern, can today do in combating AMR, focused around quality of available data, algorithms, and actual use limitations in practice. Majority of healthcare AIs are narrow artificial neural networks optimized on partial clinical datasets at risk of ingrained biases. Hastily imposed deployment threatens enhanced antimicrobial usage as well as toxicity if deceptive prediction undermines physician trust or results in new use drivers. Bulk antibiotic prescription information even comes mostly from developed world nations, which lowers model generalizability risk. Additionally, most AI antibiotic recommendatory advisors remain too opaque and lack enough explainability of underlying reasoning for clinician users. Gaining user trust is contingent upon explainable models so that recommendations in consideration can be clinically validated using available metadata. On the drug development side, even with success in scaffold prediction or mechanism elucidations, experimental validation is rather limited. Aside from technical constraints, most AI antimicrobial solutions currently continue to exist in academic research without apparent translation pathways into clinical and policy applications. Nevertheless, with cautious development and utilization, AI represents a promising pathway in the face of the urgent AMR challenge.

8. Challenges to AMR Containment

Confronting the rise of AMR involves intricate challenges with no easy solutions. Attempts to minimize human use of antimicrobials on a massive scale are hindered by their pervasive inclusion in medical care and food animal agriculture economics. Without speedy point-of-care testing, clinicians too frequently rely on empiric antibiotic treatment to protect against bacterial infection, while current farming systems condition the routine dosing of antimicrobials to animals to prevent infection and promote growth. Introduction of antimicrobial stewardship programs within healthcare and revised animal husbandry guidelines fall significantly behind in spite of recognition of resistance threats of overuse of antibiotics. To make matters worse, the antibiotic drug pipeline fails to keep up with the relentless adaptation of MDR pathogens. Drug companies more and more give up on expensive antimicrobial drug research with fewer profit motives. And although policy expansions funding antibiotic development represent improvements, short-term solutions appear doubtful in light of phase trial timeframes. Worse still for efforts at containment, global coordination for AMR surveillance and stewardship policy is piecemeal despite the acknowledgment of its transboundary risks by bodies such as the WHO, CDC, and UN. Differential access to effective diagnostics and antibiotic regulation between nations facilitates local development and worldwide diffusion of new resistance determinants. Islands of suboptimal stewardship can continually compromise and erase localized gains. Ultimately, the distinct 'tragedy of the commons' character of antibiotic resistance calls for equal, collaborative global effort and common responsibility. But geopolitical realities continue to prevent agreement on mandatory international regulations and financing pipelines necessary to consolidate antimicrobial stewardship and research across the world AMR defies territorial bounds and produces global effects in populations. Previously, infections once treatable became in recent times important health problems. The lack of effective antimicrobial drugs makes normal medical interventions, including surgery, chemotherapy, and organ transplantation, more dangerous. Besides the harmful effect on human health, AMR is also imposing significant economic burdens on health systems, governments, and society overall. The cost of dealing with resistant infections is considerably higher due to prolonged hospital stays, increased healthcare consultations, and the requirement for expensive medications as a measure of last resort.

9. Recommendations for Research and Action

The prevention of AMR requires a holistic approach that cuts across sectors and involves different stakeholders. Foremost is the need for enhanced surveillance systems to be able to observe and track the development and spread of resistant pathogens. Additionally, emphasis should be placed on the use of antimicrobials responsibly and judiciously to be able to counteract the selective pressure that drives the process of resistance. Encouragement of antimicrobial stewardship programs among healthcare facilities, along with establishment of rules regarding antibiotic use in veterinary and agriculture settings, effectively counters excessive antibiotic consumption. Executing research aimed at action is indispensable to the generation and utilization of effective measures toward diminishing antimicrobial resistance (AMR). Efforts must uncover the complex relationship between a number of factors resulting in the formation of resistance. Research into antimicrobial prescribing, agricultural use patterns, horizontal gene transfer as a mechanism for the spread of resistance, and the socio-cultural influence on antimicrobial use are integral parts of a comprehensive research strategy. Microbial ecosystem dynamics like the resistome and the effects of environmental influences are important in formulating robust strategies. It is important to build interdisciplinary collaboration among microbiologists, pharmacologists, epidemiologists, social scientists, and policymakers in order to develop a better understanding of antimicrobial resistance. The creation of novel antimicrobial medications and other treatment options is a vital component to the fight against antibiotic resistance, coupled with surveillance and diagnostic research. Drug development advancements, such as identifying new molecular targets, optimizing existing antibiotics, and exploring non-conventional therapeutic approaches like bacteriophage therapy and immunomodulation, are vital components of the field. It is important to support translational research to speed up the application of new interventions by linking laboratory findings with clinical practice. Acads, pharma companies, and regulatory authorities all have to work together to speed up the development, testing, and approval of new antimicrobial agents. Additionally, there is a pressing need to upgrade research and development activities so as to identify new antibiotics and develop new treatment regimens. There should be coordination among governments, research centers, and the drug industry for making an attempt towards motivating and expediting the production of novel antimicrobial drugs. Last but not least, one can argue that metal nanoparticles are potentially among the available therapy practices utilized in efforts to fight AMR. The use of artificial intelligence is also capable of solving the problem of high rates of AMR. In addition, it has been suggested that the simultaneous application of antibiotics and antivirulence drugs could provide improved control of pathogenic microorganisms without increasing the occurrence of AMR. Lastly, it is essential to invest resources in the development of vaccines and diagnostics to limit the dependence on antimicrobial agents and enable accurate therapeutic interventions.

10. Public Health Action and International Collaboration

Educating the public and raising awareness are vital components to combat AMR. It is the responsibility to offer the general public extensive education on the appropriate use of antibiotics, the negative consequences of their overuse, and the importance of compliance with prescribed treatment schedules. Healthcare workers should have up-to-date information on antimicrobial stewardship, infection prevention, and control strategies. Hospital antibiotic stewardship involves the creation of guidelines, education for healthcare professionals, and the execution of protocols for ensuring the proper use of antibiotics. On the other hand, outpatient settings have antibiotic stewardship focused on patient education, laboratory testing, and encouraging antibiotic use only when necessary. Through the promotion of a culture that ensures responsible antimicrobial use, it is possible to reduce the selection pressure that microbiota undergo and thereby slow down the development of antimicrobial resistance. Global cooperation is important in countering the global dimension of AMR. It is essential for governments, global institutions, and stakeholders to come together to realize regulatory harmonization, share best practices, and coordinate efforts to counter AMR effectively. Collaborative efforts, as represented by GLASS, act to enhance the sharing of data and augment the global response. Sharing of knowledge, resources, and expertise can have the potential to drive the development of holistic strategies focused on fighting AMR globally. The overall general consensus from scientists and clinicians alike is that AMR poses a significant and serious global health threat. A caveat to this point is that in the scientific community, few conflicting views or continued debates have arisen regarding the assertion. These are not necessarily in conflict with the idea that AMR is a problem. Instead, they offer differing opinions on certain aspects of the problem or offer alternative approaches to solving it. There are also differing views and debates on many aspects of AMR. They include the debate on the role of environmental determinants in AMR emergence, the feasibility of alternative treatments such as bacteriophages, the necessity to provide equal access to critical antibiotics, and the establishment of programs to curb inappropriate antibiotic use.

11. CONCLUSION

The ability of microbes and bacteria to evolve resistance quickly poses a threat to one of the cornerstones of contemporary medicine - effective antimicrobial treatment. The global human overuse of antibiotics in medicine and agriculture has imposed massive selective evolutionary pressure, allowing pathogenic bacteria to evolve multiple mechanisms for subverting once-effective antimicrobials. As antibiotic research has not kept up with increasing multidrug resistance worldwide, we have reached a perilous post-antibiotic era. Instituting stewardship programs that restrict inappropiate use of antibiotics and enhance infection control is a crucial starting point. Yet, the special 'tragedy of the commons' character of antimicrobial resistance, which crosses borders and sectors, requires binding cooperative action globally. By coordinated surveillance, access equity, conservation policy, and innovation funding implemented under a One Health framework, we can stem transmission of resistance and maintain antimicrobial effectiveness. Additional delays jeopardy projected reversions to the pre-antibiotic susceptibility bases underlying infectious disease mortality's former dominance - an event perilous to contemporary medical capabilities and worldwide health security.

REFERENCES

1. B. Sartorius, A.P. Gray, N.D. Weaver, G.R. Aguilar, L.R. Swetschinski, K.S. Ikuta, T. Mestrovic, E. Chung, E.E. Wool, C. Han, The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis, Lancet Glob. Heal 12 (2024) e201–e216.
2. A.S. Ferdinand, C. McEwan, C. Lin, K. Betham, K. Kandan, G. Tamolsaian, B. Pugeva, J. McKenzie, G. Browning, J. Gilkerson, Development of a crosssectoral antimicrobial resistance capability assessment framework, BMJ Glob. Heal 9 (2024) e013280.
3. C. Llor, L. Bjerrum, Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem, Ther. Adv. Drug Saf 5 (2014) 229–241.
4. S.A. Okaiyeto, P.P. Sutar, C. Chen, J.-B. Ni, J. Wang, A.S. Mujumdar, J.-S. Zhang, M.-Q. Xu, X.-M. Fang, C. Zhang, Antibiotic Resistant Bacteria in Food Systems: Current Status, Resistance Mechanisms, and Mitigation Strategies, Agric. Commun. (2024) 10002.
5. R.C. Founou, A.J. Blocker, M. Noubom, C. Tsayem, S.P. Choukem, M.Van Dongen, L.L. Founou, The COVID-19 pandemic: A threat to antimicrobial resistance containment, Futur Sci. OA 7 (2021) FSO736.
6. K.W.K. Tang, B.C. Millar, J.E. Moore, Antimicrobial resistance (AMR), Br. J. Biomed. Sci 80 (2023) 11387.
7. C.J.L. Murray, K.S. Ikuta, F. Sharara, L. Swetschinski, G.R. Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, Global burden of bacterial antimicrobial resistance in 2019: a

systematic analysis, Lancet 399 (2022) 629–655.

8. K.H. Luepke, K.J. Suda, H. Boucher, R.L. Russo, M.W. Bonney, T.D. Hunt, J. F. Mohr III, Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications, Pharmacother. J. Hum. Pharmacol. Drug Ther 37 (2017) 71–84.
9. K.E. Arnold, G. Laing, B.J. McMahon, S. Fanning, D.J. Stekel, O. Pahl, L. Coyne, S. M. Latham, K.M. McIntyre, The need for One Health systems-thinking approaches to understand multiscale dissemination of antimicrobial resistance, Lancet Planet Heal 8 (2024) e124–e133.
10. K.J. Maddock, C.R. Burbick, S.D. Cole, J.B. Daniels, T.E. LeCuyer, X.-Z. Li, J. D. Loy, S. Sanchez, B.L.S. Stenger, D. Diaz-Campos, A. One, Health perspective on the use of genotypic methods for antimicrobial resistance prediction, J. Am. Vet. Med. Assoc 262 (2024) 303–312.
11. M.Y. Tesema, A.G. Birhanu, One health initiative to mitigate the challenge of antimicrobial resistance in the perspectives of developing countries, Bull. Natl. Res. Cent 48 (1) (2024) 14.
12. A. Cassini, L.D. Hogberg, ¨ D. Plachouras, A. Quattrocchi, A. Hoxha, G.S. Simonsen, M. Colomb-Cotinat, M.E. Kretzschmar, B. Devleesschauwer, M. Cecchini, Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis, Lancet Infect Dis 19 (2019) 56–66.
13. R. Laxminarayan, P. Matsoso, S. Pant, C. Brower, J.-A. Røttingen, K. Klugman, S. Davies, Access to effective antimicrobials: a worldwide challenge, Lancet 387 (2016) 168–175.
14. E. Martens, A.L. Demain, The antibiotic resistance crisis, with a focus on the United States, J. Antibiot. ((((Tokyo)))) 70 (2017) 520–526.
15. M. Akova, Epidemiology of antimicrobial resistance in bloodstream infections, Virulence 7 (2016) 252–266.
16. U. Theuretzbacher, Accelerating resistance, inadequate antibacterial drug pipelines and international responses, Int. J. Antimicrob Agents 39 (2012) 295–299.
17. M. Frieri, K. Kumar, A. Boutin, Antibiotic resistance, J. Infect. Public Health 10 (2017) 369–378.
18. G. Subramaniam, M. Girish, Antibiotic resistance—A cause for reemergence of infections, Indian J. Pediatr 87 (2020) 937–944.
19. A. Shahriar, T. Akter, A.T. Kobra, T.Bin Emran, J. Mallick, M. Dutta, Isolation of pathogenic and non-pathogenic microbial stains from different types of sea fish samples and their quality assessment with antibiogram properties, J. Adv. Microbiol. 19 (2019) 1–10.
20. M.E.A. De Kraker, M. Wolkewitz, P.G. Davey, W. Koller, J. Berger, J. Nagler, C. Icket, S. Kalenic, J. Horvatic, H. Seifert, Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins, J. Antimicrob Chemother 66 (2011) 398–407.
21. S.K. Ahmed, Artificial intelligence in nursing: Current trends, possibilities and pitfalls, J. Med. Surgery, Public Heal 3 (2024) 100072.
22. H.J. Lau, C.H. Lim, S.C. Foo, H.S. Tan, The role of artificial intelligence in the battle against antimicrobial-resistant bacteria, Curr. Genet 67 (2021) 421–429.

23. J. Lv, S. Deng, L. Zhang, A review of artificial intelligence applications for antimicrobial resistance, Biosaf. Heal 3 (2021) 22–31.
24. F. Farhat, M.T. Athar, S. Ahmad, D.Ø. Madsen, S.S. Sohail, Antimicrobial resistance and machine learning: past, present, and future, Front Microbiol 14 (2023) 1179312.
25. S. He, L.G. Leanse, Y. Feng, Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases, Adv. Drug. Deliv. Rev. 178 (2021) 113922.
26. J.I. Kim, F. Maguire, K.K. Tsang, T. Gouliouris, S.J. Peacock, T.A. McAllister, A. G. McArthur, R.G. Beiko, Machine learning for antimicrobial resistance prediction: current practice, limitations, and clinical perspective, Clin. Microbiol Rev 35 (2022) e00179-21.
27. G. Liu, D.B. Catacutan, K. Rathod, K. Swanson, W. Jin, J.C. Mohammed, A. Chiappino-Pepe, S.A. Syed, M. Fragis, K. Rachwalski, Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii, Nat. Chem. Biol. (2023) 1–9.
28. T. Cai, U. Anceschi, F. Prata, L. Collini, A. Brugnolli, S. Migno, M. Rizzo, G. Liguori, L. Gallelli, F.M.E. Wagenlehner, Artificial Intelligence Can Guide Antibiotic Choice in Recurrent UTIs and Become an Important Aid to Improve Antimicrobial Stewardship, Antibiotics 12 (2023) 375.
29. Y. Kolben, H. Azmanov, R. Gelman, D. Dror, Y. Ilan, Using chronobiology-based second-generation artificial intelligence digital system for overcoming antimicrobial drug resistance in chronic infections, Ann. Med. 55 (2023) 311–318.
30. A.R. Marra, P. Nori, B.J. Langford, T. Kobayashi, G. Bearman, Brave new world: Leveraging artificial intelligence for advancing healthcare epidemiology, infection prevention, and antimicrobial stewardship, Infect. Control Hosp. Epidemiol 44 (2023) 1909–1912.

HOW TO CITE: Akshat Markam*, Swati Khare, Dr. Jitendra Banweer, Antimicrobial Resistance: Impacts, Challenges, and Future Prospects, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 5, 4527-4535. https://doi.org/10.5281/zenodo.15535325